A on NYSE

Agilent Technologies

Logo: Agilent, Public domain, via Wikimedia Commons4

American technology company

Agilent Technologies, Inc. is an American global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

$6.9BRevenue, fiscal 20255
$1.3BNet income, fiscal 20255
1999Founded1

Compare with Coherent, Inc., Avantor or Illumina, or pick any stock.

  • TickerA on NYSE1
  • Industryelectronics industry, high-performance liquid chromatography, measurement tool1
  • HeadquartersSanta Clara1
  • Websitewww.agilent.com
  • Legal formS.A.1
  • Incorporated inDE6
  • Business address5301 Stevens Creek Blvd, Santa Clara, Ca 950516
  • Filer categoryLarge accelerated filer6
Agilent-HQ-Lobby
Photo: Hathaway Dinwiddie Construction Company, Attribution, via Wikimedia Commons8

Agilent Technologies, Inc. is an American global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories. Agilent was established in 1999 as a spin-off from Hewlett-Packard. The resulting initial public offering of Agilent stock was the largest in the history of Silicon Valley at the time.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

21.3%Operating margin5
18.8%Net margin5
6.7%Revenue growth, 20255
19.3%Return on equity5
0.45×Debt to equity5
$1.2BFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Non-Instrumentation and Other brought in 65% of the revenue Agilent Technologies broke down this way in fiscal 2025.

  1. Non-Instrumentation and Other$4.5B565%up 9% from 2024
  2. Instrumentation$2.4B535%up 3% from 2024
Products and services by year
Products and services202320242025
Non-Instrumentation and Other$4.1B$4.2B$4.5B
Instrumentation$2.7B$2.4B$2.4B

Business segments

Agilent CrossLab brought in 42% of the revenue Agilent Technologies broke down this way in fiscal 2025.

  1. Agilent CrossLab$2.9B542%up 6% from 2024
  2. Life Sciences and Diagnostics Markets$2.7B539%up 11% from 2024
  3. Applied Markets$1.3B519%up 1% from 2024
Business segments by year
Business segments202320242025
Agilent CrossLab$2.7B$2.7B$2.9B
Life Sciences and Diagnostics Markets$2.8B$2.5B$2.7B
Applied Markets$1.4B$1.3B$1.3B

Regions

Rest Of World brought in 24% of the revenue Agilent Technologies broke down this way in fiscal 2025.

  1. Rest Of World$3.4B524%up 11% from 2024
  2. Americas$2.8B520%up 9% from 2024
  3. United States$2.3B517%up 4% from 2024
  4. Asia Pacific$2.2B516%up 2% from 2024
  5. Europe$1.9B514%up 9% from 2024
  6. China$1.2B59%up 1% from 2024
Regions by year
Regions202320242025
Rest Of World$3.0B$3.0B$3.4B
Americas$2.7B$2.6B$2.8B
United States$2.4B$2.2B$2.3B
Asia Pacific$2.3B$2.2B$2.2B
Europe$1.8B$1.8B$1.9B
China$1.4B$1.2B$1.2B

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue47¢$3.3B
  • Research and development6¢$455.0M
  • Selling, general and admin24¢$1.7B
  • Interest2¢$112.0M
  • Income tax2¢$132.0M
  • Profit19¢$1.3B

Out of $6.9B in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending26¢$407.0M
  • Dividends paid18¢$282.0M
  • Share buybacks27¢$425.0M
  • Kept or used elsewhere29¢$445.0M

Out of $1.6B of cash from operations.5

Financial statements

Revenue9101112135$6.9B in 2025+41% since 2018
0$2.0B$4.0B$6.0B$8.0B2018: $4.9B$4.9B20182019: $5.2B$5.2B2019+5%2020: $5.3B$5.3B2020+3%2021: $6.3B$6.3B2021+18%2022: $6.8B$6.8B2022+8%2023: $6.8B$6.8B2023−0%2024: $6.5B$6.5B2024−5%2025: $6.9B$6.9B2025+7%
Operating income9101112135$1.5B in 2025+64% since 2018
0$500.0M$1.0B$1.5B$2.0B2018: $904.0M$904.0M20182019: $941.0M$941.0M2019+4%2020: $846.0M$846.0M2020−10%2021: $1.3B$1.3B2021+59%2022: $1.6B$1.6B2022+20%2023: $1.4B$1.4B2023−17%2024: $1.5B$1.5B2024+10%2025: $1.5B$1.5B2025−1%
Net income9101112135$1.3B in 2025+312% since 2018
0$500.0M$1.0B$1.5B2018: $316.0M$316.0M20182019: $1.1B$1.1B2019+239%2020: $719.0M$719.0M2020−33%2021: $1.2B$1.2B2021+68%2022: $1.3B$1.3B2022+4%2023: $1.2B$1.2B2023−1%2024: $1.3B$1.3B2024+4%2025: $1.3B$1.3B2025+1%

Every line of the income statement in the latest annual report, as filed.5

Period ending2025-10-312024-10-312023-10-31
Net revenue$6.9B$6.5B$6.8B
Cost of revenue$3.3B$3.0B$3.4B
Research and development$455.0M$479.0M$481.0M
Selling, general and administrative$1.7B$1.6B$1.6B
Total costs and expenses$5.5B$5.0B$5.5B
Income from operations$1.5B$1.5B$1.4B
Interest income$62.0M$80.0M$51.0M
Interest expense-$112.0M-$96.0M-$95.0M
Other income (expense), net$6.0M$49.0M$33.0M
Income before taxes, as reported$1.4B$1.5B$1.3B
Provision for income taxes$132.0M$232.0M$99.0M
Net Income$1.3B$1.3B$1.2B
Net income per share - basic$4.59$4.44$4.22
Net income per share - diluted$4.57$4.43$4.19
Basic (in shares)284.0M shares290.0M shares294.0M shares
Diluted (in shares)285.0M shares291.0M shares296.0M shares

Compare Agilent Technologies with another company

The story

Founded by Bill Hewlett in 1999.1

In 1965, Hewlett-Packard branched out into scientific equipment by acquiring F&M Scientific, maker of gas chromatographs. Agilent Technologies was created in 1999 as a spin-off of several business units of Hewlett-Packard including test & measurement, optics, instrumentation and chemical analysis, electronic components, and medical equipment product lines. The split was predicated on the difficulty of growing HP's revenue stream and on the competitive vigor of smaller, more agile competitors.

The company's launch slogan was "Innovating the HP Way", which capitalized on the strong HP corporate culture called The HP Way. The starburst logo was selected to reflect "a burst of insight" (or "spark of insight") and the name "Agilent" aimed to invoke the notion of agility as a trait of the new firm. The Agilent spin-off was accompanied by an initial public offering which raised $2.1 billion, setting a record at the time.

2000–2009

In the early 2000s, "economic uncertainty" depressed demand for Agilent's products, including slow sales of health care products to hospitals in the United States, which accounted for 60% of the company's revenue at the time. The downturn also struck sales in the communications and semiconductor markets, where orders amounting to $500 million were canceled by buyers. These poor economic conditions prompted large reductions in force with 18,500 positions cut in 2003.

In 2001, in midst of this downsizing, Agilent sold its health care and medical products organization to Philips Medical Systems, and was noted as having a valuation of about $11 billion. HP Medical Products had been the second oldest part of Hewlett-Packard, acquired in the 1950s.

In August 2005, Agilent announced the sale of its business which produced semiconductor integrated circuits (known as "chips") for consumer and industrial uses to Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion. This move would involve termination of about 1,300 of the company's 28,000 employees. The group operated as a private company, Avago Technologies, until August 2009, when it was brought public in an IPO. After purchasing Broadcom Corporation in 2016, Avago changed its name to Broadcom Limited.

Also in August 2005, Agilent sold its 47% stake in the light-emitting diode manufacturer Lumileds to Philips for $1 billion. Lumileds originally started as Hewlett-Packard's optoelectronics division. Also in August 2005, Agilent announced a plan to divest its semiconductor test business, composed of both the system-on-chip and memory test market areas. Agilent listed the new company as Verigy on the Nasdaq in mid-2006.

2010 onwards

In 2009, Agilent announced the closure of a subsection of its Test & Measurement division. The product lines affected included the automated optical inspection, solder paste inspection, and automated X-ray products [5DX] in 2004. In 2011, the company, along with the University of California, Davis, announced that it would be establishing the "Davis Millimeter Wave Research Center". Agilent announced it would increase its life sciences engagement through the acquisition of Halo Genomics, based in Uppsala, Sweden, which was involved in next-generation sequencing technology development. On May 17, 2012, Agilent agreed to buy Dako, a Danish cancer diagnostics company, for $2.2 billion, to expand its presence in the life sciences industry.

On September 19, 2013, Agilent announced its decision to separate into two publicly traded companies: Agilent, a life sciences, diagnostics, and applied markets company, and Keysight, an electronic measurement company. The life sciences company retained the Agilent name and the electronic measurement company was called Keysight Technologies. On October 14, 2014, the company announced that it is exiting its Nuclear Magnetic Resonance business. On November 1, the formal separation of Agilent and Keysight Technologies was completed. Agilent announced it had completed the spin-off of its electronic measurement business, Keysight Technologies.

Read the full text

In September 2015, the company announced it would acquire Seahorse Bioscience for $235 million. On July 7, 2016, Agilent announced that it had acquired U.K. based Cobalt Light Systems, which develops and manufactures Raman spectroscopy instruments, for £40 million in cash. In December the company acquired Multiplicom N.V.

In January 2018, the company announced it would acquire Luxcel Biosciences, increasing the company's cell analysis portfolio. In May, Agilent acquired Lasergen, Inc. after the end of its two-year option on a prior investment. In the same month it acquired digital laboratory management company, Genohm, Ultra Scientific, provider of chemical standards and reference materials and Advanced Analytical Technologies, Inc. (AATI), provider of capillary electrophoresis-based molecules for $250 million in cash.

In August the company announced it would acquire glycan reagent producer, ProZyme, Inc. and South Korean instrument distributor, Young In Scientific Co. Ltd. In September Agilent acquired ACEA Biosciences for $250 million increasing the company's presence in cell analysis technologies. In August 2019, Agilent acquired US-based BioTek Instruments, a designer, manufacturer, and distributor of life science instrumentation, for $1.165 billion. On May 1, 2024, Padraig McDonnell succeeded Mike McMullen as CEO.

From Wikipedia’s article on Agilent Technologies, shared under CC BY-SA 4.0.7

Leadership

Who has led Agilent Technologies, and when. Pick a name to see everywhere that person has worked.

200020052010201520202025
Board members and other officers (13)

Products and brands

  • multi-well plate
  • plate reader
  • scientific instrument
  • software

Listed on Wikidata.1

Agilent serves analytical laboratories and the clinical and routine diagnostics markets with a full suite of technology platforms. These include: automation, bioreagents, FISH probes, gas and liquid chromatography, immunohistochemistry, informatics, mass spectrometry, microarrays, spectroscopy, target enrichment, and vacuum technologies.

Agilent also provides lab management services, including enterprise asset management, laboratory business intelligence, equipment management and service, software maintenance, regulatory compliance, sample preparation, genomics and cloning, GC and HPLC columns, spectrometry and spectroscopy supplies, and consumables. The company is known for investing in R&D within its own research labs and those of leading universities to advance the state of knowledge in the life sciences, diagnostics, and chemical analysis space.

In recent years, the company has advanced digital lab instrumentation and technology that improves lab workflow and overall efficiency and productivity. In 2020, Agilent introduced CrossLab Virtual Assist, a mobile app that facilities high-quality remote technical support. Agilent's digital advancements, including CrossLab Connect, have also improved lab optimization and sustainability by providing more efficient utilization of instruments, which can lower a lab's energy consumption.

Agilent is also a pioneer of the target enrichment used as part of a NGS workflow. The portfolio also includes sample prep, QA/QC instrumentation, 2100 bioanalyzers, and automation tools. In early 2023, the company announced a $725 million expansion of its nucleic acid-based therapeutics manufacturing facility in Frederick, Colorado.

From Wikipedia’s article on Agilent Technologies, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries

  • Agilent Technologies (Australia)
  • Agilent Technologies (Germany)
  • Agilent Technologies (India)
  • Agilent Technologies (United Kingdom)
  • Agilent Technologies (japan)
  • Stratagene California since Apr 6, 2007
  • Varian, Inc. since May 2010
  • Advanced Analytical Technologies (United States) since Mar 6, 2018
  • BioTek (company) since Jul 11, 2019

From Wikidata.1

Acquisitions

  1. Jul 11, 2019Acquired BioTek (company)1
  2. Mar 6, 2018Acquired Advanced Analytical Technologies (United States)1
  3. May 2010Acquired Varian, Inc.1
  4. Apr 6, 2007Stratagene California became a subsidiary1

Employees over time

  • 202317,6711

Former names

  • AGILENT TECHNOLOGIES INCNov 12, 1999 to Sep 16, 20196

Timeline

  1. May 1, 2024New chief executive Padraig McDonnell becomes CEO1
  2. Mar 18, 2015New chief executive Michael R. McMullen becomes CEO1
  3. Nov 18, 1999Went public Listed on NYSE1
  4. 1999Founded Founded1

Recent filings

  1. Sep 23, 2026424B3
  2. Sep 23, 2026EFFECT
  3. Sep 10, 20263 PRIMARY DOCUMENT
  4. Sep 10, 20264 PRIMARY DOCUMENT
  5. Sep 9, 20264 PRIMARY DOCUMENT
  6. Sep 8, 20268-K
  7. Sep 4, 2026144
  8. Sep 1, 202610-Q
  9. Sep 1, 2026S-3ASR
  10. Sep 1, 2026S-4
  11. Aug 26, 20268-K
  12. Jun 29, 20264 PRIMARY DOCUMENT
  13. Jun 25, 20268-K
  14. Jun 5, 20264 PRIMARY DOCUMENT
  15. Jun 5, 20263 PRIMARY DOCUMENT

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2